The primary objective of this study is as follows:
- To evaluate the safety and tolerability of XL647 administered orally as a single dose and as repeat doses in subjects with solid tumors.
The secondary objectives of this study are as follows:
- To evaluate the plasma pharmacokinetics of XL647 administered orally as a single dose and as repeat doses in subjects with solid tumors,
- To estimate renal elimination of XL647 administered orally as a single dose in subjects with solid tumors.
The exploratory objective of this study is as follows:
- To assess the pharmacodynamic effects of XL647 administration in plasma and peripheral blood cells.
In addition, subjects may be eligible to enter a Treatment Extension Period. The following information will be obtained from this part of the study:
- Long-term safety and tolerability of XL647 after repeat administration,
- Tumor response after repeat administration of XL647.